JP2009544303A - 組換え型アデノウイルスベクターの組織親和性を増大させるための方法および組成物 - Google Patents

組換え型アデノウイルスベクターの組織親和性を増大させるための方法および組成物 Download PDF

Info

Publication number
JP2009544303A
JP2009544303A JP2009521375A JP2009521375A JP2009544303A JP 2009544303 A JP2009544303 A JP 2009544303A JP 2009521375 A JP2009521375 A JP 2009521375A JP 2009521375 A JP2009521375 A JP 2009521375A JP 2009544303 A JP2009544303 A JP 2009544303A
Authority
JP
Japan
Prior art keywords
recombinant
padv
adenovirus
fiber
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544303A5 (enExample
Inventor
ジェフリー ハモンド，
マイケル エー． ジョンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of JP2009544303A publication Critical patent/JP2009544303A/ja
Publication of JP2009544303A5 publication Critical patent/JP2009544303A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Peptides Or Proteins (AREA)
JP2009521375A 2006-07-28 2007-07-27 組換え型アデノウイルスベクターの組織親和性を増大させるための方法および組成物 Pending JP2009544303A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83398506P 2006-07-28 2006-07-28
PCT/IB2007/002710 WO2008012682A2 (en) 2006-07-28 2007-07-27 Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors

Publications (2)

Publication Number Publication Date
JP2009544303A true JP2009544303A (ja) 2009-12-17
JP2009544303A5 JP2009544303A5 (enExample) 2010-08-26

Family

ID=38981845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521375A Pending JP2009544303A (ja) 2006-07-28 2007-07-27 組換え型アデノウイルスベクターの組織親和性を増大させるための方法および組成物

Country Status (12)

Country Link
US (1) US8163544B2 (enExample)
EP (1) EP2059602A4 (enExample)
JP (1) JP2009544303A (enExample)
KR (1) KR20090038910A (enExample)
CN (1) CN101849012A (enExample)
AR (1) AR062145A1 (enExample)
AU (1) AU2007278887A1 (enExample)
BR (1) BRPI0714932A2 (enExample)
CA (1) CA2658805A1 (enExample)
MX (1) MX2009000898A (enExample)
TW (1) TW200829273A (enExample)
WO (1) WO2008012682A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658805A1 (en) * 2006-07-28 2008-01-31 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
US8865182B2 (en) * 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
RU2727847C2 (ru) * 2016-05-12 2020-07-24 Биоэппликейшнз Инк. Растительная композиция для вакцинации против чумы свиней и способ ее приготовления
CN107267469B (zh) * 2017-08-22 2020-06-16 广州医科大学附属第一医院 纤毛蛋白嵌合型重组人b型腺病毒及其制备方法
CN112625095B (zh) * 2021-01-13 2023-01-03 武汉科前生物股份有限公司 一种猪轮状病毒重组蛋白以及表达该蛋白的重组腺病毒和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008706A1 (en) * 1997-08-14 1999-02-25 Commonwealth Scientific And Industrial Research Organisation Recombinant porcine adenovirus vector
WO1999055365A1 (en) * 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
WO2002024933A2 (en) * 2000-09-25 2002-03-28 Galapagos Genomics N.V. Viral vectors having tissue tropism for t-lymphocytes, b- and mast cells
US20030219899A1 (en) * 2001-04-17 2003-11-27 Nikolay Korokhov Mosaic adenoviral vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232899B2 (en) * 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
US6492343B1 (en) * 1998-04-15 2002-12-10 University Of Saskatchewan Porcine adenovirus type 3 genome
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
CA2658805A1 (en) * 2006-07-28 2008-01-31 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008706A1 (en) * 1997-08-14 1999-02-25 Commonwealth Scientific And Industrial Research Organisation Recombinant porcine adenovirus vector
WO1999055365A1 (en) * 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
WO2002024933A2 (en) * 2000-09-25 2002-03-28 Galapagos Genomics N.V. Viral vectors having tissue tropism for t-lymphocytes, b- and mast cells
US20030219899A1 (en) * 2001-04-17 2003-11-27 Nikolay Korokhov Mosaic adenoviral vectors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012045335; Ｊ．　Ｇｅｎ．　Ｖｉｒｏｌ． Ｖｏｌ．７９, 1998, ｐ．１４６１-１４６８ *
JPN6012045337; Ｊ．　Ｖｉｒｏｌ． Ｖｏｌ．７７，　Ｎｏ．２２, 2003, ｐ．１０３９-１０４８ *

Also Published As

Publication number Publication date
WO2008012682A2 (en) 2008-01-31
US8163544B2 (en) 2012-04-24
CN101849012A (zh) 2010-09-29
US20100104600A1 (en) 2010-04-29
AR062145A1 (es) 2008-10-15
EP2059602A4 (en) 2010-06-23
MX2009000898A (es) 2009-02-04
KR20090038910A (ko) 2009-04-21
WO2008012682A3 (en) 2008-06-19
BRPI0714932A2 (pt) 2013-05-21
WO2008012682A8 (en) 2009-08-13
TW200829273A (en) 2008-07-16
AU2007278887A1 (en) 2008-01-31
CA2658805A1 (en) 2008-01-31
EP2059602A2 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
CN103930551B (zh) 猴腺病毒和杂合腺病毒载体
JP7187451B2 (ja) アデノウイルスベクター
CN1869243B (zh) 基于重组猪腺病毒的病毒载体和病毒疫苗
JP5506736B2 (ja) ウシアデノウイルスタイプ３ゲノム
JP2009213495A (ja) 組換えブタ・アデノウイルス・ベクター
CA2746340A1 (en) Pcv 2-based methods and compositions for the treatment of pigs
CN111356466B (zh) 腺病毒及其用途
US8163544B2 (en) Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
AU2001263689B2 (en) Modified bovine adenovirus having altered tropism
US20030099615A1 (en) Porcine adenovirus E1 and E4 regions
AU2001263689A1 (en) Modified bovine adenovirus having altered tropism
AU780822B2 (en) Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
Wen et al. Construction and immune evaluation of the recombinant duck adenovirus type 3 delivering capsid protein VP1 of the type 1 duck hepatitis virus
JP3926887B2 (ja) 多分子発現カセット及びその利用
US7264818B2 (en) BAV packaging regions and E1 transcriptional control regions
AU757683B2 (en) Recombinant porcine adenovirus vector
US20110135688A1 (en) Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors
WO2000061773A1 (en) Recombinant and mutant adenoviruses derived of bovine adenovirus type 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120829

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130212